ライフサイエンスコーパス: vesicular stomatitis

1 mented the antiviral effects of IFN1 against vesicular stomatitis and hepatitis C viruses in human ce

2 ainst Ebola and Lassa fever VLPs, as well as vesicular stomatitis and rabies viruses (VSV and RABV, r

3 including influenza A, Zika, Ebola, Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not muri

4 se surrogate systems such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses o

5 We studied the cytotoxic activity of a vesicular stomatitis/measles hybrid virus (VSV-FH), whic

6 oma cells to infection by Lassa, measles and vesicular stomatitis pseudoviruses.

7 IDLVs pseudotyped with different envelopes (vesicular stomatitis, Rabies, Mokola and Ross River vira

8 with transient detection of the recombinant vesicular stomatitis vaccine virus in blood.

9 EPNs that incorporate the vesicular stomatitis viral glycoprotein can fuse with ta

10 Recently, we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV c

11 ough not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovir

12 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing

13 development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a singl

14 onstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has sti

15 athology after immunization with recombinant vesicular stomatitis virus (rVSV) vaccine vectors, and i

16 Recombinant vesicular stomatitis virus (rVSV) was shown to be a high

17 icacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccin

18 tenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidat

19 The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

20 approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

21 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors,

22 With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea

23 In this study, we constructed a recombinant vesicular stomatitis virus (rVSV-VP1) expressing VP1, th

24 EBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surf

25 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic duct

26 ed vaccine vectors based on live recombinant vesicular stomatitis virus (VSV) and a Semliki Forest vi

27 at intermediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (C

28 Here we report that two other RNA viruses, vesicular stomatitis virus (VSV) and encephalomyocarditi

29 n of herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) and impaired the replic

30 f green fluorescent protein (GFP)-expressing vesicular stomatitis virus (VSV) and its oncolytically e

31 ve immune functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriom

32 The active template for RNA synthesis for vesicular stomatitis virus (VSV) and other negative-stra

33 nctional L protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catal

34 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdovirus

35 d infections with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncyti

36 that two RNA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV

37 h available experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus

38 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as

39 ers, which have been employed here to purify vesicular stomatitis virus (VSV) as a model case, howeve

40 y show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-

41 Using vesicular stomatitis virus (VSV) as a model, we coinfect

42 e, we describe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeri

43 re we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) assemble to include CD4

44 Vesicular stomatitis virus (VSV) assembly requires conde

45 g ligands can be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glyc

46 Recombinant vesicular stomatitis virus (VSV) encoding the hemaggluti

47 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F a

48 ion of ACT with systemic administration of a vesicular stomatitis virus (VSV) engineered to express t

49 Vesicular stomatitis virus (VSV) exhibits a remarkably r

50 ralizing antibody titers, measured against a vesicular stomatitis virus (VSV) expressing EBGP or Delt

51 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zai

52 mental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire C

53 oped a bivalent recombinant vaccine based on vesicular stomatitis virus (VSV) expressing the Zaire eb

54 Here we describe the use of vesicular stomatitis virus (VSV) for tracing neuronal co

55 ecotropic Moloney murine leukemia virus and vesicular stomatitis virus (VSV) G glycoproteins; and (i

56 le retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G protein with dextran-

57 y(C) binding protein 2 (PCBP2) downregulates vesicular stomatitis virus (VSV) gene expression.

58 ll interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth.

59 Vesicular stomatitis virus (VSV) has been extensively st

60 Replication of vesicular stomatitis virus (VSV) has long served as a mo

61 ecause of its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a system

62 Vesicular stomatitis virus (VSV) has shown considerable

63 Vesicular stomatitis virus (VSV) has shown substantial p

64 ectious autonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprote

65 regions encompassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L prot

66 tion of Gp78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresp

67 During vesicular stomatitis virus (VSV) infection, pDC depletio

68 vely regulating the host IFN response during vesicular stomatitis virus (VSV) infection.

69 lso known as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

70 Vesicular stomatitis virus (VSV) is a bullet-shaped rhab

71 Vesicular stomatitis virus (VSV) is a highly cytopathic

72 Vesicular stomatitis virus (VSV) is a potential oncolyti

73 Vesicular stomatitis virus (VSV) is a promising oncolyti

74 Vesicular stomatitis virus (VSV) is a promising oncolyti

75 Vesicular stomatitis virus (VSV) is a promising oncolyti

76 Recombinant vesicular stomatitis virus (VSV) is a promising therapeu

77 Vesicular stomatitis virus (VSV) is a prototype nonsegme

78 Vesicular stomatitis virus (VSV) is a rhabdovirus that a

79 Vesicular stomatitis virus (VSV) is potent and a highly

80 Vesicular stomatitis virus (VSV) is the prototype for ne

81 electron cryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

82 plication-defective vaccine vectors based on vesicular stomatitis virus (VSV) lacking its envelope gl

83 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cy

84 The vesicular stomatitis virus (VSV) nucleoprotein (N) assoc

85 vaccines containing antigens from influenza, vesicular stomatitis virus (VSV) or human immunodeficien

86 n direct cell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV

87 cellular proteins from cells expressing the vesicular stomatitis virus (VSV) P protein identified th

88 Assembly of vesicular stomatitis virus (VSV) particles requires the

89 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid

90 diated degree of shielding and the amount of vesicular stomatitis virus (VSV) particles.

91 entry, 49 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and tra

92 A luciferase-expressing vesicular stomatitis virus (VSV) pseudotype that contain

93 adult flies; loss of Toll-7 led to increased vesicular stomatitis virus (VSV) replication and mortali

94 rticle RNA in HEK293 cells stably expressing vesicular stomatitis virus (VSV) replication proteins po

95 function by RNAi inhibited an early stage of vesicular stomatitis virus (VSV) replication.

96 The vesicular stomatitis virus (VSV) RNA-dependent RNA polym

97 stimulated genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable prom

98 s (MoMLV) spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cel

99 In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its n

100 study, we developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targe

101 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore

102 with miRNA inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that

103 zed the ability of a vaccine vector based on vesicular stomatitis virus (VSV) to induce a neutralizin

104 didate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that la

105 nfluenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and

106 Vesicular stomatitis virus (VSV) vectors that express he

107 rements in a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped wit

108 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its

109 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of

110 ation method is demonstrated on an RNA-based vesicular stomatitis virus (VSV) with oncolytic properti

111 Vesicular stomatitis virus (VSV), a negative-sense RNA v

112 Vesicular stomatitis virus (VSV), a negative-strand RNA

113 l proteins potently inhibit the infection of vesicular stomatitis virus (VSV), a prototype member of

114 Working with vesicular stomatitis virus (VSV), a prototype of NNS RNA

115 Vesicular stomatitis virus (VSV), a prototype of the Rha

116 Work with vesicular stomatitis virus (VSV), a prototype, supports

117 Using vesicular stomatitis virus (VSV), a prototypic NS RNA vi

118 Here we show, using vesicular stomatitis virus (VSV), a relative of rabies v

119 aviviridae, but has no appreciable effect on vesicular stomatitis virus (VSV), a rhabdovirus.

120 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer

121 K-deficient MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STIN

122 ruses, encephalomyocarditis virus (EMCV) and vesicular stomatitis virus (VSV), activate the NLRP3 inf

123 ly used to pseudotype glycoprotein-deficient vesicular stomatitis virus (VSV), allowing studies of BA

124 this observation, we engineered a strain of vesicular stomatitis virus (VSV), an oncolytic rhabdovir

125 activity of these ISGs against an RNA virus, vesicular stomatitis virus (VSV), and a DNA virus, murin

126 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothe

127 xpressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with establ

128 ombinant rabies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the

129 binant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type o

130 ced the replication of a heterologous virus, vesicular stomatitis virus (VSV), in a SOCS1-dependent m

131 RNA of negative-strand RNA viruses, such as vesicular stomatitis virus (VSV), is completely enwrappe

132 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rab

133 al infection with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

134 ted DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to protect it from nAb

135 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three

136 RdRP with those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that bo

137 cell lines and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA comple

138 By studying vesicular stomatitis virus (VSV), we identify the large

139 Working with vesicular stomatitis virus (VSV), we previously showed t

140 reporter strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinje

141 pplication of a novel viral tracer, based on vesicular stomatitis virus (VSV), which directs retrogra

142 We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expre

143 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses

144 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine

145 Using a vesicular stomatitis virus (VSV)-based pseudoparticle se

146 Here, vesicular stomatitis virus (VSV)-based pseudovirions dis

147 We produced a recombinant vesicular stomatitis virus (VSV)-based vaccine vector ex

148 antibody repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 mill

149 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVS

150 not contain the larger cargoes, collagen or Vesicular stomatitis virus (VSV)-G glycoprotein.

151 a neutralization titer of > or =1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 3

152 In the vesicular stomatitis virus (VSV)-induced encephalitis mo

153 -like helicase (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of

154 ue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta

155 We developed a recombinant vesicular stomatitis virus (VSV)-SRV vaccine consisting

156 t cell targets for the matrix (M) protein of vesicular stomatitis virus (VSV).

157 NS RNA viruses comes largely from studies of vesicular stomatitis virus (VSV).

158 r pattern was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

159 al infection by the neurotropic rhabdovirus, vesicular stomatitis virus (VSV).

160 and it inhibits the replication of HSV-1 and vesicular stomatitis virus (VSV).

161 cytopathic viruses, such as the neurotropic vesicular stomatitis virus (VSV).

162 domain of the unrelated glycoprotein (G) of vesicular stomatitis virus (VSV).

163 ensor and effector responses to intratumoral vesicular stomatitis virus (VSV).

164 ve and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

165 h influenza virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

166 ll carcinoma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

167 mouse model of prostate cancer infected with vesicular stomatitis virus (VSV).

168 results suggested a higher neutralization of vesicular stomatitis virus (VSV)/HCV E1-G pseudotype inf

169 ite-directed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA vi

170 hanisms by which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initi

171 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovir

172 se in early endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fu

173 Vesicular stomatitis virus and influenza A virus infecti

174 een after infection of IL-21R(-/-) mice with vesicular stomatitis virus and influenza virus.

175 n response to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to trans

176 ved from viral infections with influenza and vesicular stomatitis virus can persist after resolution

177 al RNA-dependent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-

178 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sol

179 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona v

180 mal human glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon

181 th rVSVDeltaG*/BDVG, a cytolytic recombinant vesicular stomatitis virus expressing BDV G that mimics

182 in lungs following intranasal infection with vesicular stomatitis virus expressing OVA and influenza

183 ne of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprot

184 ression plasmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavir

185 these MAbs to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavir

186 remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses

187 pon infection of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudo

188 F) but, surprisingly, not the trafficking of vesicular stomatitis virus G protein (VSV-G) to the cell

189 T cells are resistant to both HIV R5 env and vesicular stomatitis virus G protein (VSV-G)-mediated fu

190 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of inter

191 ination with virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promote

192 ola virus-like particles (VLPs) that express vesicular stomatitis virus G, wild-type EBOV GP (EBGP),

193 gradation of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors in

194 hen an alphavirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the o

195 Forest virus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been

196 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudoty

197 hy, we found that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased

198 rved with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycoprotein or with the amph

199 le-cycle RV complemented with a heterologous vesicular stomatitis virus glycoprotein.

200 uction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with m

201 stricted to retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

202 Vesicular stomatitis virus has been shown to bud basolat

203 tent antiviral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN rece

204 In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vect

205 wth inhibition, prolonged protection against vesicular stomatitis virus infection and enhanced transc

206 defect early after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cyto

207 CD8(+) T cell differentiation during vesicular stomatitis virus infection differed significan

208 e switched Ig in response to immunization or vesicular stomatitis virus infection is strongly impaire

209 ce in lymphocytic choriomeningitis virus and vesicular stomatitis virus infection models.

210 Furthermore, SLEC differentiation during vesicular stomatitis virus infection was enhanced by adm

211 with apoptotic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble in

212 osynthetic inhibition during influenza A and vesicular stomatitis virus infection, but not murine hep

213 Using an intranasal vesicular stomatitis virus infection, we demonstrated th

214 ation and to induce apoptosis in response to vesicular stomatitis virus infection.

215 xpression for EmGFP/IL-15 upregulation after vesicular stomatitis virus infection.

216 efractory to herpes simplex virus type 1 and vesicular stomatitis virus infection.

217 knockdown of tlr13 are highly susceptible to vesicular stomatitis virus infection.

218 Here, we define that vesicular stomatitis virus L initiates synthesis via a d

219 nfections with encephalomyocarditis virus or vesicular stomatitis virus led to higher levels of autop

220 inhibition also occurred in the presence of vesicular stomatitis virus M (matrix) protein, another v

221 mRNA export factors that are targeted by the vesicular stomatitis virus matrix protein to inhibit hos

222 es a rational approach to the attenuation of vesicular stomatitis virus neurovirulence.

223 action results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola

224 atic MAVS; challenge of transgenic mice with vesicular stomatitis virus or a synthetic HCV genome ind

225 of TRIM56 did not inhibit the replication of vesicular stomatitis virus or hepatitis C virus, a virus

226 trovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2 Abs immune-

227 Among vaccines, only the vesicular stomatitis virus platform has been successful

228 and no impact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus

229 Using vesicular stomatitis virus pseudovirions bearing EBOV gl

230 ion conferred by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack nativ

231 esis and shows reduced capability to control vesicular stomatitis virus replication and to induce apo

232 study, we found Newcastle disease virus and vesicular stomatitis virus replication is enhanced in mo

233 by IFN in both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

234 d-induced interferon production and enhanced vesicular stomatitis virus replication.

235 ession of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-ce

236 proteins from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synt

237 lescents and 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

238 Reovirus and vesicular stomatitis virus single-cycle yields were comp

239 We have used a collection of vesicular stomatitis virus strains that had been evolvin

240 RS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G

241 cipitated HIV-1 gag particles containing the vesicular stomatitis virus type G envelope, HIV-1 envelo

242 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in L

243 otective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A

244 cell lines to infection by the nonretrovirus vesicular stomatitis virus were indistinguishable.

245 whereas other RNA viruses (Sindbis virus and vesicular stomatitis virus) are not.

246 sed by two TLR3-dependent viruses (HSV-1 and vesicular stomatitis virus) were high in fibroblasts fro

247 constructs involving viral vectors (such as vesicular stomatitis virus), and antisense compounds dir

248 iruses A and B, Newcastle disease virus, and vesicular stomatitis virus), positive-sense RNA viruses

249 ve to the cytoplasmic replicating virus VSV (vesicular stomatitis virus).

250 In this article, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruse

251 he RNA-dependent RNA polymerase L protein of vesicular stomatitis virus, a prototype of nonsegmented

252 Vesicular stomatitis virus, a single-stranded RNA virus,

253 nd challenged the animals with a recombinant vesicular stomatitis virus, a synthetic HCV genome, IFN

254 d vaccinia virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, a

255 enveloped viruses (e.g., HIV, herpesviruses, vesicular stomatitis virus, and influenza virus).

256 ruses, including encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susc

257 ent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and picornaviruses as well a

258 gion I) of the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

259 ot-and-mouth disease virus, two serotypes of vesicular stomatitis virus, bluetongue virus, and bovine

260 by arboviruses, including Sindbis virus and vesicular stomatitis virus, but this innate restriction

261 d RNA virus, including influenza A virus and vesicular stomatitis virus, by a mechanism independent o

262 source antigens are expressed by vaccinia or vesicular stomatitis virus, either as proteasome-liberat

263 measles virus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus

264 ction as an entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis

265 tu formation of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A v

266 s, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or murine leukemia virus Env

267 dary challenges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispe

268 sponses than UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

269 otype nonsegmented negative-sense RNA virus, vesicular stomatitis virus, suggest a role for P beyond

270 Remarkably, infection with vesicular stomatitis virus, vaccinia virus, and a variet

271 starting with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion

272 EBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expre

273 laque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expre

274 A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a su

275 observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZE

276 32gamma protected epithelial WISH cells from vesicular stomatitis virus-induced cell death.

277 ADAM15 expression enhanced rhinovirus 16 and vesicular stomatitis virus-mediated proinflammatory cyto

278 on virus entry or coreceptor expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication

279 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-Z

280 The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly

281 2503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

282 safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

283 a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

284 of H1N1, H6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

285 ecting mice from neuropathogenesis caused by vesicular stomatitis virus.

286 ring infection by Listeria monocytogenes and vesicular stomatitis virus.

287 otection from death after CNS infection with vesicular stomatitis virus.

288 vels of RIG-I and resistance to infection by vesicular stomatitis virus.

289 the pseudotypes bearing the glycoprotein of vesicular stomatitis virus.

290 rovide an advantage for host defense against vesicular stomatitis virus.

291 n with lymphocytic choriomeningitis virus or vesicular stomatitis virus.

292 ligands but instead respond specifically to vesicular stomatitis virus.

293 is observed after intranasal challenge with vesicular stomatitis virus.

294 PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

295 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high

296 Recombinant vesicular stomatitis viruses (VSV) are excellent candida

297 Here we test replication-competent vesicular stomatitis viruses (VSV) on 19 primary human m

298 eins via replication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenovirus

299 Vesicular stomatitis viruses (VSVs) containing wild-type

300 We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatme